This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BAY 74-4113
Description: BAY 74-4113 is a DGAT-1 inhibitor. DGAT (Diglycerol Acyltransferase) is a microsomal enzyme that joins Acyl CoA to 1,2 diacylglycerol and, as such, constitutes the final step in triglyceride biosynthesis.
Deal Structure: BAY 74-4113 was originally developed by Bayer.
Bayer and Pfizer
In June 2006, Pfizer and Bayer entered into an agreement granting Pfizer exclusive worldwide rights to Bayer's DGAT-1 inhibitors, including BAY 74-4113. Under the terms of the agreement, Bayer receives an upfront fee, milestone payments and royalties on sales of any compounds successfully commercialized.
Pfizer and Bristol-Myers Squibb
In August 2007, Pfizer and Bristol-Myers Squibb announced that they finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors. The program includes DGAT-1 inhibitors in-licensed by Pfizer from Bayer Pharmaceuticals in June 2006, including PF-04415060.
Under terms of the agreement, Pfizer will be responsible for all research and early-stage development activities for the metabolic disorders program, and the companies will jointly conduct Phase III development and commercialization activities.
Partners: Bayer AG Bristol-Myers Squibb Company
Additional information available to subscribers only: